Traditional approaches to mitigating the adverse effects of eicosanoid-mediated excessive inflammatory response rely on small molecule inhibitors of COX and LOX enzymes, which can lead to worsening of pulmonary symptoms (e.g., aspirin-aggravated respiratory disease, where dysregulated ARA metabolism plays an essential role [57]). The gene discussed is LOX; the disease is respiratory system disorder.